171 related articles for article (PubMed ID: 9719502)
1. Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas.
Ma L; Ronai A; Riede UN; Köhler G
J Cancer Res Clin Oncol; 1998; 124(7):389-96. PubMed ID: 9719502
[TBL] [Abstract][Full Text] [Related]
2. Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas.
Lavieille JP; Righini C; Reyt E; Brambilla C; Riva C
Oral Oncol; 1998 Mar; 34(2):84-92. PubMed ID: 9682769
[TBL] [Abstract][Full Text] [Related]
3. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
[TBL] [Abstract][Full Text] [Related]
4. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers.
Kropveld A; Rozemuller EH; Leppers FG; Scheidel KC; de Weger RA; Koole R; Hordijk GJ; Slootweg PJ; Tilanus MG
Lab Invest; 1999 Mar; 79(3):347-53. PubMed ID: 10092071
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck.
Riedel F; Götte K; Schwalb J; Schäfer C; Hörmann K
Acta Otolaryngol; 2000 Jan; 120(1):105-11. PubMed ID: 10779196
[TBL] [Abstract][Full Text] [Related]
6. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma.
Mineta H; Borg A; Dictor M; Wahlberg P; Akervall J; Wennerberg J
Br J Cancer; 1998 Oct; 78(8):1084-90. PubMed ID: 9792155
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck.
Nylander K; Nilsson P; Mehle C; Roos G
Br J Cancer; 1995 Apr; 71(4):826-30. PubMed ID: 7710950
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of p53 protein is common in premalignant head and neck lesions.
Pavelic ZP; Li YQ; Stambrook PJ; McDonald JS; Munck-Wikland E; Pavelic K; Dacic S; Danilovic Z; Pavelic L; Mugge RE
Anticancer Res; 1994; 14(5B):2259-66. PubMed ID: 7840533
[TBL] [Abstract][Full Text] [Related]
9. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
[TBL] [Abstract][Full Text] [Related]
10. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy.
Ganly I; Soutar DS; Brown R; Kaye SB
Br J Cancer; 2000 Jan; 82(2):392-8. PubMed ID: 10646894
[TBL] [Abstract][Full Text] [Related]
11. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy.
Gallo O; Chiarelli I; Boddi V; Bocciolini C; Bruschini L; Porfirio B
Int J Cancer; 1999 Dec; 84(6):573-9. PubMed ID: 10567901
[TBL] [Abstract][Full Text] [Related]
12. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer.
van Houten VM; Tabor MP; van den Brekel MW; Kummer JA; Denkers F; Dijkstra J; Leemans R; van der Waal I; Snow GB; Brakenhoff RH
J Pathol; 2002 Dec; 198(4):476-86. PubMed ID: 12434417
[TBL] [Abstract][Full Text] [Related]
13. Changes of mutant-type p53 expression in squamous cell carcinoma of the head and neck during radiation therapy and its clinical significance: comparison of an immunohistochemical method and PCR-SSCP assay.
Ogawa Y; Nishioka A; Hamada N; Terashima M; Inomata T; Yoshida S; Seguchi H; Kishimoto S
Oncol Rep; 1998; 5(5):1053-9. PubMed ID: 9683807
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations.
Xu L; Chen YT; Huvos AG; Zlotolow IM; Rettig WJ; Old LJ; Garin-Chesa P
Diagn Mol Pathol; 1994 Jun; 3(2):83-92. PubMed ID: 8061893
[TBL] [Abstract][Full Text] [Related]
15. Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value.
Bosch FX; Ritter D; Enders C; Flechtenmacher C; Abel U; Dietz A; Hergenhahn M; Weidauer H
Int J Cancer; 2004 Sep; 111(4):530-8. PubMed ID: 15239130
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck.
Franchi A; Santucci M; Masini E; Sardi I; Paglierani M; Gallo O
Cancer; 2002 Nov; 95(9):1902-10. PubMed ID: 12404284
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
18. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck.
Nylander K; Dabelsteen E; Hall PA
J Oral Pathol Med; 2000 Oct; 29(9):413-25. PubMed ID: 11016683
[TBL] [Abstract][Full Text] [Related]
19. P53 overexpression in epidermoid carcinoma of the head and neck.
Logullo AF; Kowalski LP; Nonogaki S; Miguel RE; Torloni H; Brentani RR
Sao Paulo Med J; 1997; 115(1):1349-55. PubMed ID: 9293116
[TBL] [Abstract][Full Text] [Related]
20. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.
Koch WM; Brennan JA; Zahurak M; Goodman SN; Westra WH; Schwab D; Yoo GH; Lee DJ; Forastiere AA; Sidransky D
J Natl Cancer Inst; 1996 Nov; 88(21):1580-6. PubMed ID: 8901856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
